RVU — Ryvu Therapeutics SA Share News
0.000.00%
Last trade - 00:00- PLN319.98m
- PLN332.91m
- PLN62.25m
Brief: Ryvu Therapeutics Signs EUR 4 Mln Financial Support Deal For 'Remark' Study
Brief: Ryvu Therapeutics Q2 Net Loss Narrows To 28.5 Mln Zlotys
Ryvu and TIM to enter Warsaw's mWIG40 index
Brief: Ryvu Therapeutics Signs Two Service Deals For River-52 And River-81 Studies
Brief: Ryvu Therapeutics Signs Deal With Medical Research Agency For Up to 62.3 Mln Zloty Subsidy
Brief: Ryvu Therapeutics Secures Supply Chain For River-81 Study For About EUR 3.9 Mln
Brief: Ryvu Therapeutics Signs Two Deals With Clinscience
Brief: Ryvu Therapeutics Signs Two Deals On RVU120
Brief: Ryvu Therapeutics Recommended For 62.3 Mln Zloty Subsidy For Clinical Trial Of RVU120
Brief: Ryvu Therapeutics Q1 Net Loss Narrows To 17.6 Mln Zlotys
Brief: Ryvu Therapeutics Signs EUR 1.2 Mln Deals With Labcourp Drug Development
Brief: Galapagos NV Ends R&D Deal With Ryvu Therapeutics
Brief: Ryvu Therapeutics FY Net Loss Widens To 83.8 Mln Zlotys
Brief: Ryvu Therapeutics Concludes EUR 3.9 Mln Deal For Phase II Clinical Trial Of RVU120
Brief: Ryvu Therapeutics Achieves First Milestone Under Agreement With Exelixis
Brief: BioNTech Holds 8.29% Stake In Ryvu Therapeutics
Brief: Ryvu Therapeutics Allots 4.8 Mln J Series Shares
Brief: Ryvu Therapeutics Sets J Series Share Price For BioNTech At 48.86 Zlotys/SHR
Polish biotech firm Ryvu Therapeutics aims to raise 272 million zlotys in public offering